RTW is a Delaware limited partnership founded and principally owned by Dr. Roderick Wong
in February of 2010. Dr. Roderick Wong serves as RTW’s Managing Partner and Chief
Investment Officer. RTW provides discretionary advisory services to: RTW Master Fund, Ltd.
(“Flagship Master Fund”), RTW Offshore Fund One, Ltd. (“Flagship Offshore Fund”),
RTW Onshore Fund One, LP (“Flagship Onshore Fund”), RTW Innovation Master Fund,
Ltd. (“Innovation Master Fund”), RTW Innovation Offshore Fund, Ltd. (“Innovation
Offshore Fund”), RTW Innovation Onshore Fund, LP (“Innovation Onshore Fund”),
4010 Royalty Master Fund, LP and 4010 Royalty Investments ICAV (“Royalty Master
Funds” and, together with the Flagship Master Fund and the Innovation Master Fund”, the
“Master Funds” and each, a “Master Fund”), 4010 Royalty Offshore FNT Fund, LP
(“Royalty FNT Offshore Fund”), 4010 Royalty Offshore FT Fund, LP (“Royalty FT
Offshore Fund”, and, together with the Flagship Offshore Fund, Innovation Offshore Fund,
and Royalty FNT Offshore Fund, the “Offshore Funds” and each, an “Offshore Fund”),
4010 Royalty Onshore Fund, LP (“Royalty Onshore Fund” and, together with the Flagship
Onshore Fund and the Innovation Onshore Fund, the “Onshore Funds” and each, an
“Onshore Fund”), and RTW Co-Investment Series LLC (“Co-Investment Vehicle”),
together with the first Series company under the Co-Investment Vehicle, Ji Xing Pharmaceuticals
Series Supplement (“Ji Xing Series”), and RTW Biotech Opportunities
Ltd, formerly known as
RTW Venture Fund Limited (“Biotech Opportunities Fund”).
For the purpose of this document, the Flagship Master Fund, the Flagship Offshore Fund, and
the Flagship Onshore Fund will collectively be referred to as the “Flagship Fund,” the
Innovation Master Fund, Innovation Offshore Fund, and Innovation Onshore Fund will
collectively be referred to as the “Innovation Fund”, and the Royalty Master Funds, the
Royalty FNT Offshore Fund, the Royalty FT Offshore Fund, and the Royalty Onshore Fund
will be referred to as the “Royalty Fund”. Each respective Onshore Fund and Offshore
Fund invests a substantial portion of its assets in the related Master Fund. Unless specified,
from hereinafter the Master Funds, the Offshore Funds, the Onshore Funds, the Co-
Investment Vehicle, including the Ji Xing Series, and the Biotech Opportunities Fund will each
be referred to as a “Fund” or collectively as the “Funds.”
The Funds are managed pursuant to the objectives specified in the materials by which each
Fund offers its ownership interests to investors. RTW does not tailor its services to individual
client needs and the Funds’ investors do not have the right to specify, restrict, or influence the
Funds’ investment objectives or any investment or trading decisions.
RTW does not participate in wrap fee programs.
As of December 31, 2023, RTW had $8,820,485,054 of regulatory assets under management,
all of which were managed on a discretionary basis.